ORKA
Oruka Therapeutics, Inc.
NASDAQ: ORKA · HEALTHCARE · BIOTECHNOLOGY
$68.41
+0.46% today
Updated 2026-04-30
Market cap
$3.42B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.85
Dividend yield
—
52W range
$9 – $91
Volume
1.3M
Oruka Therapeutics, Inc. (ORKA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-24.70%
ROA
-17.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $3.89M | $-132.78M | 18.16% | -3,615.59% | -3,415.05% |
| 2007 | $46.86M | $-12.30M | 95.00% | -35.33% | -26.25% |
| 2008 | — | $-19.43M | — | — | — |
| 2009 | — | $-9.14M | — | — | — |
| 2010 | — | $-8.42M | — | — | — |
| 2011 | — | $-5.36M | — | — | — |
| 2012 | — | $-4.32M | — | — | — |
| 2013 | — | $-6.94M | — | — | — |
| 2014 | — | $-9.69M | — | — | — |
| 2015 | — | $-11.45M | — | — | — |
| 2016 | — | $-16.44M | — | — | — |
| 2017 | — | $-18.49M | — | — | — |
| 2018 | — | $-7.93M | — | — | — |
| 2019 | — | $-5.48M | — | — | — |
| 2020 | — | $-9.74M | — | — | — |
| 2021 | — | $-19.32M | — | — | — |
| 2022 | — | $-9.93M | — | — | — |
| 2023 | — | $-5.34M | — | — | — |
| 2024 | — | $-83.72M | — | — | — |
| 2025 | $0.00 | $-105.43M | — | — | — |